Due to the increasing prevalence of obesity and Type II diabetes mellitus (DM), mixed dyslipidemia characterised by high triglycerides (TG), low high-density lipoprotein cholesterol (HDL-C) and small dense low-density lipoprotein cholesterol (LDL-C) particles is becoming increasingly common 1.

The primary goal of lipid treatment is to reduce LDL-C to target levels. However, residual cardiovascular risk remains even after achievement LDL-C goal in high risk patients on statin treatment.

This residual risk may be due in part to persistently low HDL-C and high TG. Combination therapy of statins with fibrates, niacin or prescription omega-3 fatty acids may reduce this risk.